BORA PHARMACEUTICALS LTD (6472) — Cash Flow Reinvestment Rate

Latest as of March 2026: 0.45x

BORA PHARMACEUTICALS LTD (6472) has a Cash Flow Reinvestment Rate of 0.45x as of March 2026, reinvesting NT$258.50 Million (capex NT$211.08 Million plus investments NT$-47.42 Million) from operating cash flow of NT$568.46 Million. See 6472 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

0.45x
(Capex + Investments) / Operating CF

Total Reinvested

NT$258.50 Million
Capex + Investments

Operating Cash Flow

NT$568.46 Million
TWD

Capital Expenditures

NT$211.08 Million
TWD

BORA PHARMACEUTICALS LTD Cash Flow Reinvestment Rate (2019–2025)

Historical reinvestment intensity for BORA PHARMACEUTICALS LTD across 7 annual periods. For the full cash flow conversion analysis, see BORA PHARMACEUTICALS LTD cash conversion from operations.

Annual Cash Flow Reinvestment Rate for BORA PHARMACEUTICALS LTD (2019–2025)

Year-by-year capital reinvestment analysis for BORA PHARMACEUTICALS LTD. See how financially flexible is BORA PHARMACEUTICALS LTD to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (TWD) Operating CF Capex YoY Change
2025 0.22x NT$953.00 Million NT$4.24 Billion NT$928.67 Million ▼ -80.2%
2024 1.13x NT$1.11 Billion NT$980.81 Million NT$687.05 Million ▲ +254.9%
2023 0.32x NT$1.47 Billion NT$4.61 Billion NT$1.43 Billion ▲ +22.3%
2022 0.26x NT$524.20 Million NT$2.01 Billion NT$200.22 Million ▼ -11.3%
2021 0.29x NT$363.58 Million NT$1.24 Billion NT$363.58 Million ▼ -65.6%
2020 0.86x NT$152.09 Million NT$177.79 Million NT$152.09 Million ▼ -71.6%
2019 3.01x NT$697.33 Million NT$231.77 Million NT$697.33 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow